Quick Answer
Lucid Diagnostics Inc. reported Cash and Equivalents of $22.36 million for fiscal year 2024.
Lucid Diagnostics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $22.36M | +18.3% |
| 2023 | $18.90M | -15.9% |
| 2022 | $22.47M | -58.1% |
| 2021 | $53.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.33M | +226.7% | +52.1% |
| June 30, 2025 | $31.12M | +24.9% | +23.3% |
| March 31, 2025 | $25.24M | +1.9% | +12.9% |
| December 31, 2024 | $22.36M | +18.3% | +54.3% |
| September 30, 2024 | $14.49M | -39.8% | -41.9% |
| June 30, 2024 | $24.92M | -23.5% | +0.6% |
| March 31, 2024 | $24.77M | -37.3% | +31.1% |
| December 31, 2023 | $18.90M | -15.9% | -21.4% |
- Lucid Diagnostics Inc. showed an increase of +18.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2024 period, Lucid Diagnostics Inc.’s cash and equivalents has declined by 58.3% (from $53.66 million to $22.36 million).
- The most recent figure is from Lucid Diagnostics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: